President Trump has made no secret of his desire to employ Most Favored Nation (MFN) pricing for American pharmaceuticals to reign in drug costs. But tying the U.S. to prices in Europe would restrict Americans’ access to new medicines—just as it has in Europe. Rather than importing Europe’s failed ideas, President Trump and Congress should focus on the domestic policies driving U.S. drug prices up.
Read Full Article »
